Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)
Clinical trial NCT01295827 · COMPLETED
Trial details
- NCT number
- NCT01295827
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-03-04
- Primary completion
- 2018-11-05
- Enrollment
- 1260
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.